AirSculpt Technologies 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- AirSculpt Technologies reported 3rd quarter 2026 revenue of $31.9 million, down 8.7% versus the prior year quarter.
- Same-center revenue, excluding London, declined approximately 7.5%, reflecting a 9.6% decline in case volume, partially offset by a 2.3% increase in average selling price.
- Average selling price was approximately $12,900, and gross margin expanded to roughly 60% of revenue from 57.5% in the prior year quarter.
- SG&A was approximately $20.3 million, about $700,000 higher than the prior year quarter, while customer acquisition cost was roughly $3,800 per case compared with approximately $3,100 last year.
- Adjusted EBITDA was approximately $400,000, or roughly 1.2% of revenue, compared with $3 million, or 8.7% of revenue, in the prior year quarter.
- The company performed 250 GLP-1-related procedures in the quarter, representing nearly 10% of total cases.
- AirSculpt completed a refinancing through a new $44 million facility consisting of a $39 million term loan and a $5 million revolver, with maturity in 2031.
- At quarter-end, the company had approximately $15 million in cash and $20 million in total available liquidity.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings, and welcome to the AirSculpt Technologies Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Allison Malkin.
Please go ahead. Good morning, everyone.
Thank you for joining us to discuss AirSculpt Technologies' results for the third quarter of fiscal 2026. Joining me on this call today are Yogi Jashnani, Chief Executive Officer, and Michael Arthur, Chief Financial Officer. For this morning's call, Yogi will begin with a review of our third quarter results and highlight the progress made on our strategic priorities. Then Michael will share a detailed review of our third quarter performance and guidance. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth.
Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we will file with the SEC, all of which can be found on our website at investors.airsculpt.com. We undertake no obligation to revise or update any forward-looking statements or information, except as required by law. During our call today, we will also reference non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions, as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-K, which will also be available on our website. With that, I'll turn the call over to Yogi.
Thank you, Allison, and good morning, everyone. Let me start with the quarter. Our third quarter results were disappointing. While we expected a revenue decline, our performance fell short of our goals, reflecting lower productivity from our marketing investments and underperformance in a handful of clinics. We understand what drove the shortfall, and we are moving with urgency to address it. This quarter presented challenges, but it does not change our conviction in the strategy or the opportunity ahead of us. Three things reinforce that conviction. First, we performed 250 GLP-1-related procedures in the quarter, representing nearly 10% of total cases. We believe we are in the early innings of GLP-1-related aesthetic procedure growth. Second, conversion held steady, which indicates that we continue to be effective once we engage our patients. Third, we also continue to strengthen the foundation of the business.
This morning, we announced the refinancing of our term loan, extending our maturity to 2031 and giving us greater financial flexibility to support long-term growth, including de novo expansion. Now, turning to the two areas that held back performance in the quarter. The first is marketing, specifically the growing impact of Google's AI Overviews on how consumers find us. The second is performance issues in a handful of centers. Let me start with AI Overviews. AI is changing how consumers discover and evaluate aesthetic providers, and it is increasingly affecting many businesses that rely on search for discovery. According to separate industry reports, queries featuring AI Overviews have now risen to nearly 90% of healthcare-related queries. For us, this meant fewer Google clicks because Google increasingly keeps consumers on its own platform, while competition for those clicks remained unchanged.
That led to 16% lower leads versus prior year and 26% higher cost per lead in the quarter, impacting both revenue and profitability. Consumers are still interested in aesthetic procedures. We are focused on ensuring we appropriately capture that interest while the consumer search behavior is changing. We are beginning to see early signs of improvement in our presence in AI-generated search results. We are also investing more in brand and local marketing to drive traffic that does not depend on Google. Second, we experienced performance issues at a handful of centers. We recognize varying performance across centers is expected. However, this quarter, certain locations experienced operational challenges that we are working to course correct. These are within our control, and we are implementing targeted actions to improve performance at these locations. As we have shared in the past, transformations are not always linear, and this quarter reflects just that.
I remain confident that we are better positioned today with a larger addressable market and the right actions in place to achieve sustained profitable growth. Let me now turn to our progress on our three strategic priorities. As a reminder, these are, first, introducing new services to capture our GLP-1 market opportunity, enhancing our sales and marketing strategy, and maintaining strong financial discipline. First, introducing new services to capture our GLP-1 market opportunity. As a reminder, we introduced new services over the past year to capture the demand created by the GLP-1 transformation. We believe we are still in the early stages of this opportunity. According to Gallup, 11% of U.S. adults, or approximately 30 million people, were using GLP-1 medications for weight loss in 2026, up from 3% in 2024.
Additionally, McKinsey reports that 60% of U.S. consumers are actively trying to lose weight, while the American Society of Plastic Surgeons reported double-digit growth in several skin removal and lifting procedures in 2025. Longer term, we believe procedures addressing the side effects of GLP-1s continue to represent a potential $100 million revenue opportunity across our existing center base. alloClae, which we announced last quarter, is another example of our focus on serving the GLP-1 patient population. With alloClae, we can reach patients we previously could not serve, including those without enough fat for a traditional fat transfer. It is currently available in a handful of centers. While early, we are encouraged by the initial response and are expanding it across our center network.
As we evolve from traditional fat removal to a more comprehensive body contouring platform, we are learning and refining our approach to patient education and sales execution. While these newer procedures fit well within our existing business model, they require us to modify our marketing and sales compared to our traditional offerings. We are improving our ability to capture patient interest and convert that interest into completed procedures. We believe these efforts will enable us to accelerate the volume of newer procedures across our center network and increase center productivity. Our second area of focus is enhancing our sales and marketing strategy. As I mentioned earlier, we are adapting our marketing strategy to changes in how consumers discover and evaluate aesthetic procedures. We continue to optimize our website for AI-driven search, including Google AI Overviews, and are strengthening our digital content, customer reviews, and educational resources to improve visibility.
While still early, we began to see encouraging movement in certain leading indicators following these changes. We are also leveraging AI tools internally to improve patient follow-up and sales conversion, which further contributes to the relative stability in our conversion rates. In addition, we are expanding our grassroot marketing efforts to build stronger connections within the communities we serve. We are increasing our focus on localized marketing initiatives and patient education opportunities to generate awareness, drive engagement, and bring more prospective patients into our centers. Next week, on November 12, we will host our first-ever open house event across all 31 centers, bringing together surgeons and prospective patients through a combination of in-person experiences and virtual educational programming. The event is designed to engage prospective patients, reconnect with those who have previously expressed interest, and drive consultations and bookings while extending our reach through local partnerships and digital content.
As it relates to brand marketing, we expect to spend an incremental $3 million versus last year. This amount is lower than the $5 million we indicated last quarter, which we believe is prudent given the environment and current business performance. We are also focused on improving sales, productivity, and execution across our center network. To this end, we are actively implementing best practices from our stronger performing locations across the portfolio to improve sales effectiveness and conversion. Turning to our third priority, maintaining strong financial discipline. As I mentioned earlier, we have completed the refinancing of our existing term loan, providing greater financial flexibility to support our long-term strategy, including future de novo expansion. Michael will share more details on this shortly. We continue to make progress strengthening our financial position and ended the quarter with approximately $15 million in cash and $20 million in total available liquidity.
While our near-term focus remains on improving same-center sales and strengthening execution across our existing centers, we continue to view de novo expansion, additional service lines, and strategic partnerships as a meaningful long-term growth opportunity. In summary, while our third quarter proved more challenging, we continue to see evidence that our GLP-1 strategy is the right one, with growing demand from these patients and increasing traction across our expanded procedure offerings. We continue to make progress advancing our strategic initiatives and strengthening the foundation of our business. We are implementing targeted marketing initiatives and taking steps to improve performance across our centers. Our updated outlook contemplates third quarter performance trends continue into the fourth quarter, which we believe is prudent. That said, we are intently focused on returning to stability and accelerating our path to growth.
With that, I will now turn the call over to Michael to review our third quarter financial results and outlook.
Thank you, Yogi, and good morning, everyone. I would like to begin with this morning's announcement that we completed our debt refinancing. This has been a priority for us over the last nine months, and we are pleased with the results. The new $44 million facility, made up of $39 million term loan and a $5 million revolver, matures in 2031 and gives us greater long-term financial flexibility. We filed the credit agreement this morning under an eight-K with the SEC. This is a significant milestone, and it is worth putting in context. We successfully deleveraged over the last two years, and that combined with improved financial performance and stabilization we achieved over the past nine months is what allowed us to complete this refinance on the terms we did. With that, let me walk through the third quarter results.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
